GlassScriptPhysician profile
Andrew Cochrane
NPI 1972560001
$1,748.94
in general payments reported to CMS, 2019-2025
14 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $14.44 · 2021: $165 · 2022: $274 · 2023: $410 · 2024: $270 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $510.86 | 2019-2025 | Cequa, Xelpros |
| Abbvie INC. | $206.70 | 2022-2025 | |
| Alcon Vision LLC | $192.48 | 2022-2025 | Rocklatan, Eysuvis, Simbrinza |
| Allergan, INC. | $179.56 | 2019-2022 | |
| Oyster Point Pharma, INC. | $148.03 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $117.97 | 2023-2025 | Vyzulta, Xiidra |
| Tarsus Pharmaceuticals, INC. | $107.47 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $86.99 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $52.56 | 2019 | |
| Rxsight INC | $46.41 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Aerie Pharmaceuticals, INC. | $44.56 | 2020-2021 | |
| Thea Pharma INC. | $24.02 | 2025 | Iyuzeh |
| Shire North American Group INC | $18.84 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Cochrane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.